Lack of association between the angiotensin-converting enzyme insertion/deletion polymorphism and plasminogen activator inhibitor-1 antigen levels in the National Heart, Lung, and Blood Institute Family Heart Study

James S. Pankow, D. K. Arnett, I. B. Borecki, Steven Hunt, J. H. Eckfeldt, A. R. Folsom, L. Djoussé

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Experimental and clinical research supports a direct link between activation of the renin-angiotensin system and production of plasminogen activator inhibitor-1 (PAI-1), the primary physiologic inhibitor of tissue plasminogen activator. Several studies have reported higher PAI-1 levels in individuals carrying the deletion (D) allele of the angiotensin-converting enzyme (ACE) gene. We investigated the association between ACE genotypes and plasma PAI-1 levels in a family study of 577 women and 428 men from four US communities. Participants were between 25 and 84 years of age without evidence of coronary heart disease (CHD). Mean geometric plasma PAI-1 levels adjusted for ethnicity were 17.4, 17.9, and 18.1 ng/ml in participants with the DD, insertion-deletion (ID), and II genotypes, respectively (P = 0.89 for difference). We found no associations between ACE I/D genotypes and plasma PAI-1 antigen concentrations in a subset of participants without major CHD risk factors (hypertension, hypercholesterolemia, overweight, smoking, diabetes) or in a small sample of African-Americans. Our findings suggest that the ACE insertion/deletion polymorphism has relatively little, if any, influence on circulating PAI-1 levels in the population at large. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish
Pages (from-to)551-558
Number of pages8
JournalBlood Coagulation and Fibrinolysis
Volume11
Issue number6
DOIs
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Plasminogen Activator Inhibitor 1
Peptidyl-Dipeptidase A
Antigens
Genotype
Coronary Disease
Tissue Plasminogen Activator
Renin-Angiotensin System
Hypercholesterolemia
African Americans
Smoking
Alleles
Hypertension
Research
Population
Genes

Keywords

  • Angiotensin-converting enzyme
  • Plasminogen activator inhibitor-1
  • Polymorphism

ASJC Scopus subject areas

  • Hematology

Cite this

Lack of association between the angiotensin-converting enzyme insertion/deletion polymorphism and plasminogen activator inhibitor-1 antigen levels in the National Heart, Lung, and Blood Institute Family Heart Study. / Pankow, James S.; Arnett, D. K.; Borecki, I. B.; Hunt, Steven; Eckfeldt, J. H.; Folsom, A. R.; Djoussé, L.

In: Blood Coagulation and Fibrinolysis, Vol. 11, No. 6, 2000, p. 551-558.

Research output: Contribution to journalArticle

@article{fc771e08e2ef447fa6f8d32a53f9868c,
title = "Lack of association between the angiotensin-converting enzyme insertion/deletion polymorphism and plasminogen activator inhibitor-1 antigen levels in the National Heart, Lung, and Blood Institute Family Heart Study",
abstract = "Experimental and clinical research supports a direct link between activation of the renin-angiotensin system and production of plasminogen activator inhibitor-1 (PAI-1), the primary physiologic inhibitor of tissue plasminogen activator. Several studies have reported higher PAI-1 levels in individuals carrying the deletion (D) allele of the angiotensin-converting enzyme (ACE) gene. We investigated the association between ACE genotypes and plasma PAI-1 levels in a family study of 577 women and 428 men from four US communities. Participants were between 25 and 84 years of age without evidence of coronary heart disease (CHD). Mean geometric plasma PAI-1 levels adjusted for ethnicity were 17.4, 17.9, and 18.1 ng/ml in participants with the DD, insertion-deletion (ID), and II genotypes, respectively (P = 0.89 for difference). We found no associations between ACE I/D genotypes and plasma PAI-1 antigen concentrations in a subset of participants without major CHD risk factors (hypertension, hypercholesterolemia, overweight, smoking, diabetes) or in a small sample of African-Americans. Our findings suggest that the ACE insertion/deletion polymorphism has relatively little, if any, influence on circulating PAI-1 levels in the population at large. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Angiotensin-converting enzyme, Plasminogen activator inhibitor-1, Polymorphism",
author = "Pankow, {James S.} and Arnett, {D. K.} and Borecki, {I. B.} and Steven Hunt and Eckfeldt, {J. H.} and Folsom, {A. R.} and L. Djouss{\'e}",
year = "2000",
doi = "10.1097/00001721-200009000-00007",
language = "English",
volume = "11",
pages = "551--558",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Lack of association between the angiotensin-converting enzyme insertion/deletion polymorphism and plasminogen activator inhibitor-1 antigen levels in the National Heart, Lung, and Blood Institute Family Heart Study

AU - Pankow, James S.

AU - Arnett, D. K.

AU - Borecki, I. B.

AU - Hunt, Steven

AU - Eckfeldt, J. H.

AU - Folsom, A. R.

AU - Djoussé, L.

PY - 2000

Y1 - 2000

N2 - Experimental and clinical research supports a direct link between activation of the renin-angiotensin system and production of plasminogen activator inhibitor-1 (PAI-1), the primary physiologic inhibitor of tissue plasminogen activator. Several studies have reported higher PAI-1 levels in individuals carrying the deletion (D) allele of the angiotensin-converting enzyme (ACE) gene. We investigated the association between ACE genotypes and plasma PAI-1 levels in a family study of 577 women and 428 men from four US communities. Participants were between 25 and 84 years of age without evidence of coronary heart disease (CHD). Mean geometric plasma PAI-1 levels adjusted for ethnicity were 17.4, 17.9, and 18.1 ng/ml in participants with the DD, insertion-deletion (ID), and II genotypes, respectively (P = 0.89 for difference). We found no associations between ACE I/D genotypes and plasma PAI-1 antigen concentrations in a subset of participants without major CHD risk factors (hypertension, hypercholesterolemia, overweight, smoking, diabetes) or in a small sample of African-Americans. Our findings suggest that the ACE insertion/deletion polymorphism has relatively little, if any, influence on circulating PAI-1 levels in the population at large. (C) 2000 Lippincott Williams and Wilkins.

AB - Experimental and clinical research supports a direct link between activation of the renin-angiotensin system and production of plasminogen activator inhibitor-1 (PAI-1), the primary physiologic inhibitor of tissue plasminogen activator. Several studies have reported higher PAI-1 levels in individuals carrying the deletion (D) allele of the angiotensin-converting enzyme (ACE) gene. We investigated the association between ACE genotypes and plasma PAI-1 levels in a family study of 577 women and 428 men from four US communities. Participants were between 25 and 84 years of age without evidence of coronary heart disease (CHD). Mean geometric plasma PAI-1 levels adjusted for ethnicity were 17.4, 17.9, and 18.1 ng/ml in participants with the DD, insertion-deletion (ID), and II genotypes, respectively (P = 0.89 for difference). We found no associations between ACE I/D genotypes and plasma PAI-1 antigen concentrations in a subset of participants without major CHD risk factors (hypertension, hypercholesterolemia, overweight, smoking, diabetes) or in a small sample of African-Americans. Our findings suggest that the ACE insertion/deletion polymorphism has relatively little, if any, influence on circulating PAI-1 levels in the population at large. (C) 2000 Lippincott Williams and Wilkins.

KW - Angiotensin-converting enzyme

KW - Plasminogen activator inhibitor-1

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=0033835756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033835756&partnerID=8YFLogxK

U2 - 10.1097/00001721-200009000-00007

DO - 10.1097/00001721-200009000-00007

M3 - Article

VL - 11

SP - 551

EP - 558

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 6

ER -